Trials of Novartis' Dupixent rival bet scrapped by MorphoSys, Galapagos

MorphoSys and Galapagos are cutting off development of their Novartis-backed drug MOR106 in atopic dermatitis.

The cull comes after the three were hit by analysis done in the middle of its phase 2 test, which showed it was likely to fail.